TrialAntimicrobial agents and chemotherapy2025
Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial.
Matthew Tate et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.